title: Lipoprotein and apolipoprotein levels in postmenopausal women on continuous oestrogen/progestogen therapy.
abstract: Levels of serum lipoproteins and apolipoproteins were monitored for 48 weeks in two groups of women taking part in a double-blind trial of continuous oestrogen/progestogen with and without oestriol. There were no differences between the effects of the two treatments on the substances measured. Triglycerides did not change and there was a transient fall in very low density lipoprotein cholesterol. Low density lipoprotein cholesterol fell over the first 24 weeks but rose thereafter to pretreatment levels. There was a decrease in high density lipoprotein (HDL) cholesterol due to a transient fall in HDL2 cholesterol and a gradual decrease in HDL3 cholesterol. Consequently, the only change in lipid levels present after 48 weeks was a decrease in HDL3 cholesterol, the clinical significance of which is uncertain. There was, however, an increase in apoprotein B levels and decreases in apoprotein AI and AII levels. These alterations in apoprotein levels may be unfavourable, since apoprotein B levels have been positively correlated and apoprotein AI and AII levels negatively correlated with coronary heart disease.
authors.affiliation: Department of Biochemistry, Stobhill General Hospital, Glasgow.
authors.forename: E
authors.initials: E
authors.lastname: Farish
authors.forename: C D
authors.initials: CD
authors.lastname: Fletcher
authors.forename: M M
authors.initials: MM
authors.lastname: Dagen
authors.forename: D M
authors.initials: DM
authors.lastname: Hart
authors.forename: F
authors.initials: F
authors.lastname: Al-Azzawi
authors.forename: D E
authors.initials: DE
authors.lastname: Parkin
authors.forename: C A
authors.initials: CA
authors.lastname: Howie
mesh_terms: D001053:Apolipoproteins / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D004958:Estradiol / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008593:Menopause / Q000097:blood*; D009640:Norethindrone / Q000627:therapeutic use; D011897:Random Allocation
chemical_list: D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D004967:Estrogens; D008074:Lipoproteins; D004958:Estradiol; D004964:Estriol; D009640:Norethindrone